Pfizer Recalls More Quinapril Due to Potential Carcinogen Pfizer Recalls More Quinapril Due to Potential Carcinogen
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 27, 2022 Category: Endocrinology Tags: Cardiology News Source Type: news

Accupril Recall; USPSTF Finalizes Aspirin Recs; Cardiologist's COVID Fraud
(MedPage Today) -- Nitrosamines struck again, forcing Pfizer to recall five lots of the antihypertensive medication quinapril HCl (Accupril), according to the FDA. Consistent with draft recommendations released last fall, the U.S. Preventive Services... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 26, 2022 Category: Cardiology Source Type: news

Pfizer Recalls Another Blood Pressure Medication
Pfizer is recalling five lots of blood pressure medicine Accupril because of elevated levels of a nitrosamine, Nnitroso-quinapril, the company said in a news release posted on the FDA website. (Source: WebMD Health)
Source: WebMD Health - April 25, 2022 Category: Consumer Health News Source Type: news

Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL ® (Quinapril HCl) Due to N-Nitroso-Quinapril Content
Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, Nnitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 23, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pfizer Voluntary Nationwide Recall of Lots of Accuretic (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-Nitroso-Quinapril Content
Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient(consumer/user) level due to the presence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 5, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Class 2 Medicines Recall: Pfizer Limited, Accuretic 10/12.5 mg film-coated tablets
Pfizer Ltd are recalling batch number DD4842 as a precautionary measure due to the identification of a nitrosamine above the acceptable limit. Following testing, N-nitroso-quinapril, has been observed (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 28, 2022 Category: Drugs & Pharmacology Source Type: news

Pfizer Recalling 3 Blood Pressure Medication Types Due To Cancer Concerns, FDA Says
This time the culprit is a nitrosamine, N-nitroso-quinapril, being present in quantities above Acceptable Daily Intake (ADI) levels. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 26, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news

Pfizer Voluntary Nationwide Recall of Lots of ACCURETICTM (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-NitrosoQuinapril Content
Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient(consumer/user) level due to the presence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 22, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pfizer Recalls BP Drugs Because of Potential Carcinogen Pfizer Recalls BP Drugs Because of Potential Carcinogen
The voluntary nationwide recall of the antihypertensive Accuretic and two generics was prompted by unacceptable levels of N-nitroso-quinapril, a likely carcinogen, in 11 lots.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news

quinapril (Accupril)
Title: quinapril (Accupril)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/5/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 5, 2019 Category: Cardiology Source Type: news

Accuretic (Quinapril HCl/Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news

Accupril (Quinapril Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 24, 2017 Category: Drugs & Pharmacology Source Type: news

quinapril, Accupril
Title: quinapril, AccuprilCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/30/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 30, 2014 Category: Drugs & Pharmacology Source Type: news

quinapril, Accupril
Title: quinapril, AccuprilCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/30/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 30, 2014 Category: Cardiology Source Type: news